Leap Therapeutics is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
May 11, 2018Leap Therapeutics Reports First Quarter 2018 Financial Results
April 16, 2018Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
March 27, 2018Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 23, 2018Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
March 22, 2018Leap Therapeutics Announces Proposed Public Offering of Common Stock
March 21, 2018Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
March 14, 2018Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
March 07, 2018Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference
February 23, 2018Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders
February 06, 2018Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
January 16, 2018Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
as of 4:00 PM ETMay 25, 2018
Data provided by Nasdaq. Minimum 15 minutes delayed.